{"id":"W3170157997","doi":"10.1007/s40273-021-01027-4","title":"Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Novartis Pharmaceuticals Corporation","keywords":"Fulvestrant; Medicine; Hazard ratio; Oncology; Metastatic breast cancer; Discontinuation; Internal medicine; Breast cancer; Cancer; Progression-free survival; Quality-adjusted life year; Letrozole; Cost effectiveness; Gynecology; Estrogen receptor; Tamoxifen; Confidence interval; Overall survival","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001561964,0.0002682628,0.0008425147,0.0001299869,0.0000556386,0.000005965351,0.00009709642,0.0000418886,0.000101608],"category_scores_gemma":[0.00001237998,0.0001808294,0.00005293804,0.0002032812,0.0001879296,0.0001282585,0.000008192493,0.0001231309,2.618007e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002773525,"about_ca_system_score_gemma":0.002706859,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.03844422,"about_ca_topic_score_gemma":0.1007815,"domain_scores_codex":[0.9986291,0.0001052917,0.0003966072,0.0003697769,0.0001200804,0.0003791368],"domain_scores_gemma":[0.9978786,0.0003844377,0.000350003,0.0002688288,0.0009444826,0.0001736427],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.3681128,0.005543308,0.05445858,0.002018291,0.005427297,0.00009023023,0.02361228,0.008519922,0.09898026,0.0005212603,0.000003046486,0.4327128],"study_design_scores_gemma":[0.1163502,0.02564809,0.4063393,0.001770123,0.0005174757,0.0002752274,0.01258378,0.001593115,0.4322674,0.0001924052,0.001841059,0.0006217355],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9893654,0.00226556,0.0001109019,0.003064009,0.00007151515,0.003485877,0.001590262,0.00001075433,0.00003570487],"genre_scores_gemma":[0.9934912,0.004223267,0.000774266,0.0002332107,0.00006308567,0.001004176,0.0000597158,0.00006248644,0.00008857745],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.432091,"threshold_uncertainty_score":0.9679589,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03336379531504483,"score_gpt":0.35892055458306,"score_spread":0.3255567592680152,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}